• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

EBioMedicine . Epigenome-wide association study of COVID-19 severity with respiratory failure

tetano

Editor, Senior Moderator
EBioMedicine


. 2021 Apr 14;103339.
doi: 10.1016/j.ebiom.2021.103339. Online ahead of print.
Epigenome-wide association study of COVID-19 severity with respiratory failure


Manuel Castro de Moura[SUP] 1 [/SUP], Veronica Davalos[SUP] 1 [/SUP], Laura Planas-Serra[SUP] 2 [/SUP], Damiana Alvarez-Errico[SUP] 1 [/SUP], Carles Arribas[SUP] 1 [/SUP], Montserrat Ruiz[SUP] 2 [/SUP], Sergio Aguilera-Albesa[SUP] 3 [/SUP], Jes?s Troya[SUP] 4 [/SUP], Juan Valencia-Ramos[SUP] 5 [/SUP], Valentina V?lez-Santamaria[SUP] 6 [/SUP], Agust? Rodr?guez-Palmero[SUP] 7 [/SUP], Judit Villar-Garcia[SUP] 8 [/SUP], Juan P Horcajada[SUP] 8 [/SUP], Sergiu Albu[SUP] 9 [/SUP], Carlos Casasnovas[SUP] 6 [/SUP], Anna Rull[SUP] 10 [/SUP], Laia Reverte[SUP] 10 [/SUP], Beatriz Dietl[SUP] 11 [/SUP], David Dalmau[SUP] 12 [/SUP], Maria J Arranz[SUP] 13 [/SUP], Laia Lluci?-Carol[SUP] 14 [/SUP], Anna M Planas[SUP] 15 [/SUP], Jordi P?rez-Tur[SUP] 16 [/SUP], Israel Fernandez-Cadenas[SUP] 14 [/SUP], Paula Villares[SUP] 17 [/SUP], Jair Tenorio[SUP] 18 [/SUP], Roger Colobran[SUP] 19 [/SUP], Andrea Martin-Nalda[SUP] 20 [/SUP], Pere Soler-Palacin[SUP] 20 [/SUP], Francesc Vidal[SUP] 10 [/SUP], Aurora Pujol[SUP] 21 [/SUP], Manel Esteller[SUP] 22 [/SUP]



Affiliations

Abstract

Background: Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19), exhibit a wide spectrum of disease behaviour. Since DNA methylation has been implicated in the regulation of viral infections and the immune system, we performed an epigenome-wide association study (EWAS) to identify candidate loci regulated by this epigenetic mark that could be involved in the onset of COVID-19 in patients without comorbidities.
Methods: Peripheral blood samples were obtained from 407 confirmed COVID-19 patients ? 61 years of age and without comorbidities, 194 (47.7%) of whom had mild symptomatology that did not involve hospitalization and 213 (52.3%) had a severe clinical course that required respiratory support. The set of cases was divided into discovery (n = 207) and validation (n = 200) cohorts, balanced for age and sex of individuals. We analysed the DNA methylation status of 850,000 CpG sites in these patients.
Findings: The DNA methylation status of 44 CpG sites was associated with the clinical severity of COVID-19. Of these loci, 23 (52.3%) were located in 20 annotated coding genes. These genes, such as the inflammasome component Absent in Melanoma 2 (AIM2) and the Major Histocompatibility Complex, class I C (HLA-C) candidates, were mainly involved in the response of interferon to viral infection. We used the EWAS-identified sites to establish a DNA methylation signature (EPICOVID) that is associated with the severity of the disease.
Interpretation: We identified DNA methylation sites as epigenetic susceptibility loci for respiratory failure in COVID-19 patients. These candidate biomarkers, combined with other clinical, cellular and genetic factors, could be useful in the clinical stratification and management of patients infected with the SARS-CoV-2.
Funding: The Unstoppable campaign of the Josep Carreras Leukaemia Foundation, the Cellex Foundation and the CERCA Programme/Generalitat de Catalunya.

Keywords: COVID-19; Coronavirus; DNA methylation; Epigenetics; SARS-CoV-2.
 
Back
Top Bottom